Our findings in the MESA cohort are consistent with those reported in the PREVEND study in that higher baseline hs-cTnT and NT-proBNP levels among participant free of clinical CVD had increased risks for all cancers and colorectal cancer, independent of traditional CVD risk factors. This evidence concerns the gene TNNT2 and cancer.